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Purpose
We compared the treatment results and toxicity in nasopharyngeal carcinoma (NPC) patients
treated with concurrent chemotherapy (CCRT) alone (the CRT arm) or neoadjuvant
chemotherapy followed by CCRT (the NCT arm).
Materials and Methods
A multi-institutional retrospective study was conducted to review NPC patterns of care and
treatment outcome. Data of 568 NPC patients treated by CCRT alone or by neoadjuvant
chemotherapy followed by CCRT were collected from 15 institutions. Patients in both treat-
ment arms were matched using the propensity score matching method, and the clinical
outcomes were analyzed.
Results
After matching, 300 patients (150 patients in each group) were selected for analysis. Higher
5-year locoregional failure-free survival was observed in the CRT arm (85% vs. 72%,
p=0.014). No significant differences in distant failure-free survival (DFFS), disease-free sur-
vival (DFS), and overall survival were observed between groups. In subgroup analysis, the
NCT arm showed superior DFFS and DFS in stage IV patients younger than 60 years. No
significant difference in compliance and toxicity was observed between groups, except the
radiation therapy duration was slightly shorter in the CRT arm (50.0 days vs. 53.9 days,
p=0.018).
Conclusion
This study did not show the superiority of NCT followed by CCRT over CCRT alone. Because
NCT could increase the risk of locoregional recurrences, it can only be considered in 
selected young patients with advanced stage IV disease. The role of NCT remains to be 
defined and should not be viewed as the standard of care.
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Introduction
Nasopharyngeal carcinoma (NPC) is a relatively rare dis-
ease in South Korea, and accounts for 7.2% to 23.1% of head
and neck cancers [1,2]. According to the Korean National
Cancer Registry Report in 2011, its incidence in South Korea
was 0.8 per 100,000 [3], lower than in endemic areas, such as
southern China, southeast Asia, and north Africa, but higher
than that of Western countries [2,4]. NPC in endemic areas
differs from Western NPC in that more than 90% of patients
have non-keratinizing and undifferentiated carcinoma,
which is more frequently related to Epstein-Barr virus (EBV)
[1]. Although South Korea is a non-endemic area, some clin-
icopathologic characteristics of NPC are shared with NPC in
endemic areas, including strong relation with EBV and a
lower prevalence of keratinizing carcinoma than in Western
countries [1,2].
NPC is usually considered unresectable because of its
anatomical location, thus radiation therapy (RT) plays a
major role in its treatment [5,6]. The current standard treat-
ment strategy for locally advanced NPC is concurrent
chemoradiotherapy (CCRT) with or without adjuvant chem-
otherapy, which was determined based on the superior 
results of randomized trials comparing RT alone and CCRT
[7-9]. However, even when treated with CCRT, 3-year pro-
gression-free survival (PFS) is still only around 70% [7,8]. 
Recent advances in RT technology, such as intensity-modu-
lated radiation therapy (IMRT), make it possible to increase
the radiation dose with the same or lower toxicity and
achieve higher local control rates [5,10]. In addition, because
of the high rate of distant metastasis in NPC patients, there
is a resurgence of interest in adjuvant and neoadjuvant chem-
otherapy (NCT) for advanced NPC in combination with
CCRT. However, because of the diverse chemotherapy regi-
mens, schedules, and mixed results reported, it is difficult 
to determine whether adjuvant chemotherapy or NCT can
improve treatment outcome in NPC [5,11-16]. 
In this study, we compared the treatment results and tox-
icities of CCRT alone (CRT arm) and NCT followed by CCRT
(NCT arm) in primary NPC patients.
Materials and Methods
1. Patients
To review the NPC patterns of care and treatment out-
comes in South Korea, a multi-institutional retrospective
study (Korean Radiation Oncology Group [KROG] 11-06)
was conducted through the Head and Neck Committee of 
Korean Society of Radiation Oncology (KOSRO). Data of
1474 primary NPC patients treated at 15 institutions in South
Korea between September 1988 and October 2011 were col-
lected. Clinical and pathological data were collected from
medical records. All patients satisfied the following criteria:
(1) biopsy-proven NPC; (2) stage I to IVb according to the
American Joint Committee on Cancer (AJCC) cancer staging,
6th edition; (3) age over 18 years; and (4) Eastern Cooperative
Oncology Group system (ECOG) performance status (PS) 
! 2. Patients who had undergone previous surgery, radio-
therapy to the head and neck, and those with distant metas-
tasis before treatment initiation were excluded. 
Prior to patient enrollment, institutional review board 
approval was obtained at each participating center and data
were transferred to the KROG Data Center (National Cancer
Center, Goyang, Korea). Radiotherapy, chemotherapy, toxi-
city, recurrence, and survival reports of all patients were 
reviewed according to a centralized quality-assurance pro-
gram.
For this study, we selected 583 patients who satisfied the
following inclusion criteria: (1) stage II to IVb by the AJCC
cancer staging, 6th edition; (2) treated by CCRT alone or NCT
followed by CCRT; and (3) non-receipt of any type of adju-
vant chemotherapy after CCRT. Of these 583 patients, 15 
patients with insufficient data for analysis of treatment out-
come were excluded. The remaining 568 patients were finally
included in the analysis, 380 patients were included in the
CRT arm and 188 patients in the NCT arm.
2. Patient selection using the propensity score matching
method
Because parts of the baseline characteristics between the
CRT and NCT arm were statistically different, including his-
tologic type, hospital size, and RT techniques (Table 1), the
propensity score matching (PSM) method was used to con-
trol the imbalance. Nine covariates were entered in the
propensity model, including age, sex, hospital size, ECOG
PS, histologic type, T stage, N stage, RT technique, and the
CCRT regimen. Propensity scores were calculated using a
non-parsimonious multivariable logistic regression model to
estimate the conditional probability. Then a 1:1 match 
between the CRT and NCT arm was performed using the
nearest available neighbor matching. After PSM, 150 pairs of
patients were matched successfully, and 300 patients were
included for analysis.
3. Study endpoints and statistical analysis
We analyzed the patients and treatment characteristics,
compliances, toxicities, and treatment outcomes. Histologic
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Table 1. Baseline patient characteristics in the pre- and post-propensity score matching cohort
Characteristic Before propensity score matching After propensity score matching
CRT (n=380) NCT (n=188) p-value CRT (n=150) NCT (n=150) p-value
Sex
Male 266 (70.0) 144 (76.6) 0.099 111 (74.0) 111 (74.0) > 0.999
Female 114 (30.0) 44 (23.4) 39 (26.0) 39 (26.0)
Age
Median (range, yr) 52 (19-86) 50 (20-73) 0.223 51.5 (19-77) 50 (19-72) 0.648
Mean±SD 51.4±13.1 50.0±12.1 50.8±13.2 50.5±11.6
ECOG PS
0 65 (17.1) 34 (18.1) 0.539 27 (18.0) 25 (16.7) 0.963
1 303 (79.7) 151 (80.3) 119 (79.3) 122 (81.3)
2 12 (3.2) 3 (1.6) 4 (2.7) 3 (2.0)
WHO histology
I 77 (20.3) 17 (9.0) < 0.001 15 (10.0) 17 (11.3) 0.502
IIa 108 (28.4) 75 (39.9) 59 (39.3) 58 (38.7)
IIb 187 (49.2) 84 (44.7) 70 (46.7) 71 (47.3)
Not classified 8 (2.1) 12 (6.4) 6 (4.0) 4 (2.7)
T stage
1 95 (25.0) 54 (28.7) 0.308 38 (25.3) 40 (26.7) 0.389
2 102 (26.8) 39 (20.7) 34 (22.7) 34 (22.7)
3 86 (22.6) 39 (20.7) 36 (24.0) 35 (23.3)
4 97 (25.5) 56 (29.8) 42 (28.0) 41 (27.3)
N stage
0 44 (11.6) 16 (8.5) 0.366 15 (10.0) 13 (8.7) 0.410
1 104 (27.4) 50 (26.6) 42 (28.0) 41 (27.3)
2 172 (45.3) 98 (52.1) 71 (47.3) 75 (50.0)
3 60 (15.8) 24 (12.8) 22 (14.7) 21 (14.0)
AJCC stage
II 38 (10.0) 13 (6.9) 0.480 14 (9.3) 12 (8.0) 0.914
III 194 (51.1) 99 (52.7) 77 (51.3) 79 (52.7)
IV 148 (38.9) 76 (40.4) 59 (39.3) 59 (39.3)
Hospital size
Large 264 (69.5) 104 (55.3) 0.001 97 (64.7) 93 (62.0) 0.637
Small 116 (30.5) 84 (44.7) 53 (35.3) 57 (38.0)
RT method
Non-IMRT 231 (60.8) 63 (33.5) < 0.001 52 (34.7) 57 (38.0) 0.456
IMRT 149 (39.2) 125 (66.5) 98 (65.3) 93 (62.0)
CRT regimen
Cisplatin alone 322 (84.7) 159 (84.6) 0.883 131 (87.3) 126 (84.0) 0.411
Combined 58 (15.3) 29 (15.4) 19 (12.7) 24 (16.0)
NCT regimen
FP - 36 (19.1) N/A - 32 (21.3) N/A
F or P+taxane - 64 (34.0) - 61 (40.7)
FP+taxane - 78 (41.4) - 48 (32.0)
Other - 10 (5.3) - 9 (6.0)
Values are presented as number (%) unless otherwise indicated. CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant
chemotherapy arm; SD, standard deviation; ECOG PS, Eastern Cooperative Oncology Group performance status; WHO,
World Health Organization; AJCC, American Joint Committee on Cancer; RT, radiation therapy; IMRT, intensity-modulated
radiotherapy; F, 5-fluorouracil; P, cisplatin; N/A, not assessed.
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type was defined according to the World Health Organiza-
tion (WHO) classification 2005 [17]. Tumor responses were
recorded according to WHO criteria [18]. Acute and late
treatment toxicities were assessed using the National Cancer
Institute’s Common Terminology Criteria for Adverse
Events (CTCAE) ver. 3.0 [19]. Only the incidences of toxicities
! grade 3 were recorded.
Overall survival (OS) was defined as the time from patho-
logic diagnosis of NPC to any cause of death; all deaths from
any cause were counted as events and patients who 
remained alive were treated as censored at the date of last
follow-up. Disease-free survival (DFS) was defined as time
from pathologic diagnosis to time of first failure at any site
or any death. Locoregional  failure-free survival (LRFFS) and
distant failure-free survival (DFFS) were also analyzed, and
were defined as any recurrence in the nasopharyngeal
and/or cervical region or any failure at a distant site. Sur-
vival proportions were estimated using the Kaplan-Meier
method.
Standardized differences were estimated for all baseline
covariates before and after matching to assess pre-match 
imbalance and post-match balance. In the matched data,
paired comparisons were performed using McNemar’s test
for binary variables and Wilcoxon signed rank test for con-
tinuous variables. The log-rank test and the Cox proportional
hazards model were used to identify prognostic factors inde-
pendently associated with survival and to estimate hazard
ratios (HR). Two-sided p-values of < 0.05 were considered
statistically significant. Statistical analyses were performed
using the software package SPSS ver. 21.0 (SPSS Inc.,
Chicago,  IL) or R software ver. 2.15.3 (R Foundation for Sta-
tistical Computing, Vienna, Austria; http://www.r-project.
org).
Results
1. Patients and treatment characteristics
A summary of patient and treatment characteristics before
and after PSM is shown in Table 1. Of 300 patients selected
after PSM, there were 222 male patients (74.0%) with a 
median age of 51 years (range, 19 to 77 years). The ECOG PS
were 0-1 in 293 patients (97.6%), and 2 in only seven patients
(2.3%). WHO type I (keratinizing carcinoma) tumors were
found in 32 patients (10.7%), and were evenly distributed
after PSM. The AJCC tumor stage was II in 26 patients (8.7%),
III in 156 patients (52.0%), and IV in 118 patients (39.3%).
More patients in the NCT arm were treated with IMRT at
small hospitals before PSM of which "small" means the 
average number of daily treated RT patients is under 100.
After PSM, patients were evenly distributed, and 191 patients
(63.7%) were treated with IMRT. The most commonly used
chemotherapy regimen during the CCRT was cisplatin alone
for 257 patients (85.7%). During NCT, taxane combined with
cisplatin or 5-fluorouracil (5-FU), or both was most fre-
quently used in 109 patients (62.7%). The other 41 patients
(27.3%) received a non-taxane containing regimen during
NCT. 
2. Response and survival
Tumor response data were collected only after completion
of CCRT, and not after completion of NCT. It was evaluated
in 290 patients (96.7%) after median 1.4 months follow-up
(range, 0.1 to 39.0 months), and showed similar results 
between groups with no statistical difference (p=0.180).
Complete response was achieved in 87 patients (60.0%) in the
CRT arm, and 92 patients (63.4%) in the NCT arm. Objective
response (complete or partial response) was achieved in 140
patients (96.6%) in the CRT arm, and 142 patients (97.9%) in
the NCT arm. Progressive disease was found in two patients
(1.4%), and both patients were in the NCT arm and had stage
IV disease.
The OS, DFS, LRFFS, and DFFS between treatment arms
are shown in Fig. 1 after a median follow-up of 35.9 months
(range, 6.4 to 18.2 months) in the CRT arm, and 33.8 months
(range, 6.4 to 152.6 months) in the NCT arm. The 5-year
LRFFS was 85% in the CRT arm and 72% in the NCT arm,
which was a statistically significant difference (p=0.014).
Compared to LRFFS, lower 5-year DFFS was observed in the
CRT arm compared with the NCT arm (65% vs. 76%); how-
ever, it was not statistically significant (p=0.390). No differ-
ence in OS and DFS was observed between the CRT and
NCT arm. The 5-year OS and DFS were 72.1%, 52.2% in the
CRT arm, and 81.1%, 57.1% in the NCT arm, respectively
(p=0.340 and p=0.978, respectively).
3. Prognostic factors affecting survival
The results of multivariate analysis of the prognostic fac-
tors on survival are shown in Table 2. The T and N stage
were significant factors affecting the survival. The T stage 
affected not only the LRFFS but also the DFFS, DFS, and OS,
while the N-stage affected the DFFS and DFS only. The dif-
ference of LRFFS between treatment arms also showed sta-
tistical significance in multivariate analysis with HR of 2.21
(95% confidence interval [CI], 1.19 to 4.12; p=0.012). Other
factors including sex, ECOG PS, WHO histology, and RT
method did not show statistical significance in multivariate
analysis. 
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4. Subgroup analysis
In subgroup analysis by sex (male vs. female), PS (ECOG
0-1 vs. 2), histology (WHO type I vs. type II), the results of
survival outcome between the CRT and NCT arm were sim-
ilar. However, the results were different in AJCC stage IV
subgroup and in patients younger than 60 years (Table 3). In
AJCC stage IV patients (59 patients in each arm), the LRFFS,
PFS, and OS did not differ between two arms. However, bet-
ter 5-year DFFS was observed in the NCT arm compared to
the CRT arm (47.3% vs. 75.8%) even though it did not reach
statistical significance (p=0.088). In young patients under 60
years, no negative effect of NCT on LRFFS was observed
(p=0.314). Therefore, in patients younger than 60 years with
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Fig. 1. Overall survival (OS) (A), disease-free survival (DFS) (B), locoregional failure-free survival (LRFFS) (C), and distant
failure-free survival (DFFS) (D) curves for the concurrent chemoradiotherapy arm (CRT) and neoadjuvant chemotherapy
arm (NCT) arms in the propensity-matched cohort.
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AJCC stage IV disease, the adjusted HR for DFFS was 0.46
(95% CI, 0.21 to 0.99; p=0.049). The DFS also favored NCT
arms in these patients with HR of 0.56 (95% CI, 0.30 to 1.02)
with marginal significance (p=0.058). However, the OS was
not different. The survival outcomes of these patients are
shown in Fig. 2. 
5. Compliance and toxicity
Because only patients who had completed their RT sched-
ule were selected after PSM, the compliance was analyzed
on the whole patient cohort and is shown in Table 4. Of the
568 patients, 15 patients (2.6%) did not receive the planned
RT dose and treatment was interrupted. Seven of these 15
patients were in the CRT arm, and eight were in the NCT
arm. A higher percentage was observed in the NCT arm
(4.3% vs. 1.8%), but without statistical significance (p=0.091).
The reasons for RT interruption were poor general condition
(9 patients), severe mucositis (2 patients), patient refusal 
(2 patients), and renal failure (1 patient). Durations of RT
were similar in the two arms with an average of 53.5 days in
the CRT arm and 52.8 days in the NCT arm for the entire 
cohort (p=0.621). However, in the PSM cohort, the average
RT duration was 3.9 days longer in the NCT arm (50.0 vs.
53.9 days, p=0.018). 
The chemotherapy schedule during CCRT was interrupted
in 94 patients (16.5%), 61 patients in the CRT arm and 33 
patients in the NCT arm. Chemotherapy tolerance during
Cancer Res Treat. 2016;48(3):917-927
Table 2. Multivariate analysis of prognostic factors in the propensity-matched cohort
Overall survival Disease-free survival Locoregional DistantFactor failure-free survival       failure-free survival
Adjust HR p-value Adjust HR p-value Adjust HR p-value Adjust HR p-value
Treatment arm (CRT vs. NCT) 0.74 (0.53-1.30) 0.297 1.02 (0.70-1.47) 0.939 2.21 (1.19-4.12) 0.012 0.84 (0.52-1.38) 0.844
Sex (male vs. female) 1.46 (0.7-2.75) 0.246 0.90 (0.58-1.41) 0.648 1.25 (0.65-2.42) 0.503 0.61 (0.31-1.18) 0.140
Age (< 60 yr vs. ! 60 yr) 1.02 (1.00-1.05) 0.087 1.01 (0.99-1.03) 0.258 1.03 (1.00-1.05) 0.069 1.00 (0.98-1.02) 0.841
ECOG PS (0-1 vs. 2) 0.63 (0.08-4.91) 0.662 1.26 (0.45-3.55) 0.662 2.13 (0.48-9.48) 0.319 0.92 (0.22-3.90) 0.913
WHO histology (I vs. II) 1.32 (0.55-3.19) 0.535 1.21 (0.68-2.15) 0.528 1.10 (0.45-2.67) 0.830 1.81 (0.76-4.30) 0.180
T stage (1-2 vs. 3-4) 2.54 (1.38-4.70) 0.003 2.28 (1.53-3.39) < 0.001 2.16 (1.16-4.01) 0.015 2.11 (1.26-3.53) 0.005
N stage (0-1 vs. 2-3) 1.56 (0.85-2.89) 0.153 2.00 (1.30-3.08) 0.002 1.47 (0.76-2.82) 0.252 2.30 (1.29-4.10) 0.005
RT method (non-IMRT vs. IMRT) 0.93 (0.52-1.69) 0.819 1.00 (0.67-1.49) 0.996 0.99 (0.53-1.85) 0.970 0.94 (0.56-1.58) 0.821
HR, hazard ratio; CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant chemotherapy arm; ECOG PS, Eastern 
Cooperative Oncology Group performance status; WHO, World Health Organization; RT, radiation therapy; IMRT, inten-
sity-modulated radiotherapy.
Table 3. Subgroup analysis by prognostic factors in the propensity-matched cohort
Overall survival Disease-free survival Locoregional DistantFactor (CRT vs. NCT arm) failure-free survival       failure-free survival
Adjust HR p-value Adjust HR p-value Adjust HR p-value Adjust HR p-value
Age
< 60 yr (116 vs. 110) 0.78 (0.38-1.58) 0.486 0.79 (0.50-1.24) 0.302 1.48 (0.69-3.19) 0.314 0.64 (0.36-1.15) 0.138
! 60 yr (44 vs. 40) 0.80 (0.32-2.02) 0.804 1.65 (0.85-3.21) 0.138 4.04 (1.33-12.26) 0.014 1.48 (0.58-3.76) 0.407
AJCC stage
II-III (91 vs. 91) 0.45 (1.67-1.21) 0.116 1.28 (0.74-2.19) 0.378 3.34 (1.33-8.37) 0.010 1.06 (0.53-2.11) 0.873
IV (59 vs. 59) 1.08 (0.53-2.16) 0.840 0.80 (0.47-1.34) 0.390 1.49 (0.62-3.57) 0.377 0.54 (0.27-1.09) 0.088
Age < 60 yr and 0.81 (0.33-2.02) 0.652 0.56 (0.30-1.02) 0.058 1.06 (0.36-3.08) 0.918 0.46 (0.21-0.99) 0.049
AJCC stage IV (44 vs. 46)
CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant chemotherapy arm; HR, hazard ratio; AJCC, American Joint
Committee on Cancer.
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CCRT was similar in the two arms for any chemotherapy
regimen (Table 4). Five patients (2.7%) received only one
cycle of the planned NCT course because of no response or
progression in four patients and nephrotoxicity in one.
Acute and late toxicities are shown in Table 5. Toxicity was
analyzed in the PSM cohort to balance the use of IMRT and
the difference of chemotherapy regimen. The most frequent
! grade 3 acute toxicities were neutropenia and mucositis.
Incidences of ! grade 3 acute toxicity showed no difference
between the treatment arms. However, higher incidence of
! grade 4 hematologic toxicity was observed in the NCT arm
(3.3% vs. 0.7%). The most frequent late toxicity was xerosto-
mia, followed by soft tissue fibrosis, radiation necrosis, and
ototoxicity. However, the most fatal toxicities were radiation
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Fig. 2. Overall survival (OS) (A), disease-free survival (DFS) (B), locoregional failure-free survival (LRFFS) (C), and distant
failure-free survival (DFFS) (D) curves for the concurrent chemoradiotherapy arm (CRT) and neoadjuvant chemotherapy
arm (NCT) arms in subgroup with stage IV disease patients younger than 60 years.
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Table 4. Radiotherapy and chemotherapy compliance in the entire cohort
Type of treatment CRT (n=380) NCT (n=188) p-value
Radiation interruption 7 (1.8) 8 (4.3) 0.091
Duration, mean (range, day)
Entire cohort 53.5 (17-165) 52.8 (13-158) 0.621
PSM cohort 50.0 (31-98) 53.9 (34-117) 0.018
Chemotherapy during CRT
Total interruption 61 (16.1) 33 (17.6) 0.651
Cisplatin weekly
1-4 cycles 24 (18.8) 23 (21.9) 0.550
! 5 cycles 104 (81.2) 82 (78.1)
Cisplatin, every 3 wk
1 cycle 17 (8.9) 3 (5.7) 0.447
! 2 cycles 174 (91.1) 50 (94.3)
Platinum+5-FU or taxane
1-2 cycles 15 (40.5) 5 (35.7) 0.752
! 3 cycles 22 (59.5) 9 (64.3)
Chemotherapy during NCT
1 cycle - 5 (2.7) -
2 cycles - 35 (22.9)
! 3 cycles - 148 (77.1)
Values are presented as number (%) unless otherwise indicated. CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant
chemotherapy arm; PSM, propensity score matching; 5-FU, 5-fluorouracil.
Table 5. Grade 3 or higher acute and late toxicity in the propensity-matched cohort
Type of toxicity CRT (n=150) NCT (n=150) p-value
Acute toxicity (grade 3/4)
Hematologic
Grade 3 17 (11.3) 18 (12.0) 0.857
Grade 4 1 (0.7) 5 (3.3) 0.214
Anorexia/Nausea/Vomiting 5 (3.3) 2 (1.3) 0.448
Mucositis/Odynophagia 27 (18.0) 29 (19.3) 0.767
Dermatitis 4 (2.7) 6 (4.0) 0.750
Xerostomia 4 (2.7) 4 (2.7) > 0.999
Any acute toxicity 57 (38.0) 59 (39.3) 0.813
Late toxicity (grade 3/4)
Soft tissue fibrosis 5 (3.3) 3 (2.0) 0.723
Radionecrosis/Neuropathy 2 (1.3) 1 (0.7) > 0.999
Xerostomia 6 (4.0) 7 (4.7) 0.777
Ototoxicity 1 (0.7) 2 (1.3) > 0.999
Any late toxicity 14 (9.3) 13 (8.7) 0.840
Grade 5 toxicity
Radionecrosis/Neuropathy 0 ( 2 (1.3) 0.498
Neutropenia/Infection 1 (0.7) 0 ( > 0.999
Not reported 2 (1.3) 2 (1.3) > 0.999
Any grade 5 toxicity 3 (2.0) 4 (2.7) > 0.999
Values are presented as number (%). Treatment toxicities were assessed using the National Cancer Institute’s Common Ter-
minology Criteria for Adverse Events (ver. 3.0). CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant chemotherapy
arm.
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necrosis and neutropenia. Overall, treatment-related death
occurred in seven patients (2.3%). No difference in late toxi-
city was observed between treatment arms.
Discussion
To improve the treatment outcomes of NPC, the addition
of adjuvant chemotherapy or NCT to CCRT has been widely
studied [5]. NCT is believed to be superior to adjuvant
chemotherapy in some theoretical aspects: (1) compliance
with the entire course of chemotherapy is higher for NCT;
(2) penetration of chemotherapeutic agents into tumor tis-
sues might be limited due to the disruption of native blood
vessels after RT; and (3) NCT might kill subclinical 
micrometastases before definitive local treatment [5,20]. For
these reasons, NCT has been an attractive strategy for many 
researchers.
Before the Intergroup 0099 study, which showed superior
results for CCRT as compared with RT alone [7], several
studies compared NCT followed by RT and RT alone. 
Although a reduction in relapse-free and disease-specific sur-
vival was observed with NCT in some studies, no differences
in OS or treatment failure pattern were observed [21,22]. 
After CCRT became the standard treatment for advanced
NPC, there were questions with regard to whether addition
of NCT to CCRT could improve outcomes, and, as a result,
several phase II trials were conducted. Hui et al. [11] reported
on a comparative randomized phase II study on NCT with 
docetaxel and cisplatin (TP) followed by CCRT versus CCRT
alone. Three-year DFS was not significantly different (88.2%
in the NCT arm and 59.5% in the CRT arm, p=0.12). How-
ever, 3-year OS was statistically superior in the NCT arm
(94.1% vs. 67.7%).
The Hellenic Cooperative Oncology Group (HeCOG) also
reported the results of a comparative phase II study on NCT
with a cisplatin/epirubicin/paclitaxel regimen followed by
CCRT versus CCRT alone [14]. In analysis of the data of 141
patients, no difference in terms of compliance, response, 
3-year DFS and OS was observed between the two arms. 
A meta-analysis on 11 studies conducted by Liang et al.
[15], which included 1096 NPC patients, compared the 
results of NCT followed by CCRT versus CCRT with or with-
out adjuvant chemotherapy. This study also showed that
NCT followed by CCRT did not significantly improve OS,
LRFFS, or DFFS. 
In the current study, we also failed to demonstrate a better
outcome for NCT versus CCRT alone. Although the DFFS,
DFS, and OS did not differ between groups, lower LRFFS
was observed in the NCT arm. This result seems to reflect
the theoretical disadvantages of NCT. The disadvantages of
NCT include the selection of resistant tumor cell clones, trig-
gering accelerated repopulation, and reduced compliance
and increased toxicity during CCRT. 
In our study, even though the toxicities were similar 
between the two arms, RT was interrupted more frequently
in the NCT arm (4.3%) than in the CRT arm (1.8%), and the
overall treatment time of RT was also longer in the NCT arm
in the PSM cohort. In our study, in comparison of the local
control rate according to RT duration, significantly lower
LRFFS was observed in patients with RT duration longer
than 50 days (82.8% vs. 73.3%, p=0.034). The advantage of
NCT by reducing the distant failure was only observed in
stage IV disease patients and those younger than 60 years.
This result of subgroup analysis was consistent with that of
the study reported by Zhang et al. [23]. They also conducted
a PMS study of NPC patients in China, which showed 
improved DFFS only in T4N1-2 or N3 patients (86.1% vs.
74.9%, p=0.034), favoring NCT. 
However, there are some limitations of our study that war-
rant consideration. First, the heterogeneous NCT regimen
could diminish the positive effect of NCT. Non-taxane con-
taining regimen was also used in 27.3% of patients, which
was unfavorable if we consider the recent impressive out-
comes by addition of taxane to the NCT regimens. In the
EORTC 24971/TAX 323 study, triple combinations of doc-
etaxel, cisplatin, and 5-FU (TPF) showed superior PFS and
OS rates compared with cisplatin and 5-FU in other head and
neck cancers [24]. Based on these findings, Ekenel et al. [13]
used TP for the NCT regimen in NPC patients, and reported
a 3-year OS of 94.9% and a PFS of 84.7%. Bae et al. [12], who
also reported the results of NCT using the TPF regimen fol-
lowed by CCRT in Korea, achieved 3-year OS and PFS rates
of 86.1% and 75.6%, respectively [12], which were slightly
lower than results obtained in endemic areas, but were nev-
ertheless remarkable.
The second limitation of our study was the relatively 
imperfect data on toxicity. This was due to the retrospective
nature of data collection from several institutions, and it 
resulted in comparative low toxicity rates than other litera-
tures. However, similar toxicity rates between two treatment
arms have also been reported in other studies. The HeCOG
group study reported no significant differences in acute tox-
icities after CCRT [14], even though thrombocytopenia was
more common in the NCT arm and dermatitis was more
common in the CRT arm. However, the rates of all other tox-
icities were similar in both arms. In a meta-analysis con-
ducted by Liang et al. [15], the toxicity results showed that
the risk ratio of grade 3-4 neutropenia was 1.90 (95% CI, 1.24
to 2.92) in favor of the CRT arm rather than the NCT arm.
However, other toxicities were similar.
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Conclusion
In conclusion, this study did not show the superiority of
NCT followed by CCRT over CCRT alone. Because NCT
could increase the risk of locoregional  recurrences, it can
only be considered in selected young patients with advanced
stage IV disease. The role of NCT in addition to CCRT 
remains to be defined and is currently not the standard of
care. The results of phase III trials are needed in order to
draw a firm conclusion.
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